An Overview of the Treatment Landscape for EGFR-mutated NSCLC

Opinion
Video

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing improved efficacy compared with earlier options.

Video content above is prompted by the following:

  • Please give an overview of the treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC).
Recent Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.